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Beta-adrenergic blocking agents, nitrates and calcium
channel antagonists are effective in treating angina pec-
toris, but much remains unknown about how they act
in combination. Consequently, treadmill exercise was
used to assess the relative efficacy of nifedipine or iso-
sorbide dinitrate, or both, in 19 patients with stable
angina receiving propranolol. Propranolol therapy was
continued and either placebo, nifedipine (20 mg), iso-
sorbide dinitrate (20 mg) or both drugs were given ran·
domly Ilf2 hours before exercise in a double-blind trial.
In 16 patients who completed the protocol, heart rate at
rest during propranolol therapy was 53.7 ± 1.9 beats/min
(mean ± standard error of the mean); it increased 4.6
± 1.2 beats/min with the addition of nifedipine (p <
0.01), but was unchanged with isosorbide dinitrate or
both combined. Compared with values during treatment
with propranolol alone, systolic blood pressure at rest
Conventional medical therapy of chronic angina pectoris
includes the use of beta-adrenergic blocking agents and long-
acting nitrates, either alone or in combination, The intro-
duction of calcium channel antagonists has provided an ad-
ditional mode of therapy for this disorder, but much remains
to be learned about their therapeutic efficacy when used in
conjunction with the more established agents, It has been
shown that combination therapy with propranolol and iso-
sorbide dinitrate (1,2) or propranolol and nifedipine (3-6),
significantly improves exercise tolerance in patients with
exercise-induced angina compared with propranolol alone,
However, information on effects of combining all three
agents is lacking. This study was designed to compare the
relative efficacy of nifedipine and isosorbide dinitrate in
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decreased with each vasodilator individually and when
combined. Rate-pressure product at maximal exercise
was the same with all combinations.
Exercise duration was 467 ± 50 seconds with pro-
pranolol, increased to 556 ± 47 seconds with isosorbide
dinitrate (p < 0.05) and to 636 ± 50 seconds with ni-
fedipine (p < 0.001). Exercise duration with all three
drugs was 597 ± 47 seconds (p < 0.01 compared with
propranolol alone). The improvement with nifedipine
was greater than with isosorbide dinitrate (p < 0.05)
but exercise duration was not significantly different with
the combination of these drugs than when either drug
was used alone. Exercise duration was actually worse in
9 of 16 patients when all three drugs were given than
with the two drug combination of propranolol and ni-
fedipine. Thus, in an individual patient, combining all
three agents does not necessarily optimize therapy.
patients with chronic stable angina pectoris taking propran-
olol. In addition, the combination of both vasodilators (ni-
fedipine and isosorbide dinitrate) with propranolol was eval-
uated for possible additive, synergistic or antagonistic effects.
Methods
Patient selection. Informed consent was obtained from
19 male patients whose ages ranged from 45 to 68 years
(mean 58,8), In all patients exercise was limited by classic
exertional angina pectoris before entry into the study, An-
giographic evidence of significant coronary artery disease
was documented in 15 of the 19 patients who had undergone
cardiac catheterization; the remaining 4 patients had classic
positive exercise tests with angina and ischemic electrocar-
diographic changes during exercise, Eight patients had pre-
vious myocardial infarction and six patients had undergone
coronary artery bypass surgery, None had clinical or radio-
logic evidence of cardiac enlargement, congestive heart fail-
ure, intermittent claudication, significant valvular heart dis-
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ease, recent myocardial infarction or hypertension requiring
vasodilator therapy.
Seventeen of the 19 patients were taking long-acting ni-
trates, and 6 were taking nifedipine. Both drugs were with-
drawn at least 24 hours before entry into the study. All
patients were receiving long-term propranolol therapy with
a minimal total daily dose of 160 mg before entry, and were
maintained on their usual dosage throughout the study. Sub-
lingual nitroglycerin was available for treatment of angina,
but in no instance was it required during the 10 hours pre-
ceding each exercise test. Administration of diuretic agents
(nine patients) and digoxin (one patient) was continued, but
no other cardiovascular medications were used during the
study.
Protocol. The study was double-blind, randomized and
placebo-controlled. Each patient was studied daily for 4 days
starting at 7 a.m. when heart rate and blood pressure were
recorded. Exercise testing was performed in the morning
after an overnight fast. The patient was then given a slurry
of propranolol and either nifedipine (20 mg), isosorbide
dinitrate (20 mg), placebo or both nifedipine (20 mg) and
isosorbide dinitrate (20 mg) in orange juice. Acetaminophen
(650 mg) was given concomitantly with the isosorbide di-
nitrate to prevent headache. Blood pressure and heart rate
were recorded at least every IS minutes until the exercise
test was performed.
The exercise test was performed according to a modified
Naughton protocol (Table I) I V2 hrs after the administration
of the morning test medications. This time interval was
chosen on the basis of the pharmacokinetics of nifedipine
(7), isosorbide dinitrate (8) and propranolol (9), to represent
a time when all three drugs would be at effective serum
concentrations.
Accurate comparison ofthe clinical efficacy ofnijedipine
and isosorbide dinitrate in patients receiving propranolol
is difficult because complete dose-response curves for all
these agents have not been ascertained. The test dose of
isosorbide dinitrate was chosen on the basis of the work of
Thadani et al. (10), who found that "the acute effects of
isosorbide dinitrate on treadmill walking time to angina were
not dose-related. A single dose of IS mg produced an im-
Table 1. Modified Naughton Protocol for Treadmill Exercise
Stage Speed (mph) Slope (%) Duration (min)
I 1.5 0 2
II 2.0 0 2
III 2.0 3.5 2
IV 2.0 7.0 2
V 3.0 5.0 2
VI 3.0 10.0 2
VII 3.0 12.5 2
VIII 3.0 15.0 2
provement in exercise performance similar to that seen after
single doses of 30, 60, and 120 mg." Correlation of nifed-
ipine dose with therapeutic response has also been studied,
but reports are conflicting (11,12). We elected to study the
commonly used dose of 20 mg. The dose of propranolol
was not standardized for each patient because the relation
between clinical response and daily propranolol dosage is
subject to great individual variability (13,14). Rather, the
dose was individualized to achieve adequate beta-adrenergic
blockade as evidenced by control of rest and exercise heart
rate before entry into the study. This dose was then main-
tained throughout the study.
Patients were instructed to grade their chest pain on a
oto 5 scale where grade 2 represents chest pain of sufficient
severity that the patient usually stops exercise and takes a
nitroglycerin tablet. All patients exercised to symptom-tol-
erated maximal exercise consisting of grade 2 chest pain or
inability to continue because of dyspnea, leg fatigue, or
both.
Statistical analysis. Statistical analysis was performed
using analysis of variance for repeated measures on the same
elements (15). Differences were considered statistically sig-
nificant for probability (p) values less than 0.05.
Results
Symptoms and side effects. Of the 19 patients with
stable angina pectoris who were randomized, 16 completed
the study. One patient who previously received nifedipine,
propranolol and long-acting nitrates developed unstable an-
gina while receiving propranolol alone, was dropped from
the study, restarted on his previous medication and referred
for surgery. During the study, two patients developed sig-
nificant symptomatic hypotension after receiving the com-
bination of all three drugs. Both patients had previously
tolerated separate doses of nifedipine and isosorbide dini-
trate. Systolic blood pressures recorded during these hy-
potensive episodes were in the 70 to 80 mm Hg range which
precluded exercise testing. Side effects in the other 16 pa-
tients were relatively minor and well tolerated. One patient
reported lightheadedness with placebo. There was one com-
plaint of headache and one of lightheadedness with isosor-
bide dinitrate. With nifedipine, four patients became light-
headed (including one who was also slightly nauseated) and
another became nauseated. With triple drug therapy, six
patients became lightheaded or dizzy, and these symptoms
were often orthostatic.
Symptoms during exercise. During treatment with pro-
pranolol alone, all patients stopped exercising because of
angina. While receiving both isosorbide dinitrate and pro-
pranolol, one patient completed the exercise protocol and
the others stopped because of angina. In contrast, with ni-
fedipine 9 of the 16 patients stopped exercise for reasons
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Figure 1. Effect of various combinations of propranolol (P), iso-
sorbide dinitrate (1) and nifedipine (N) on values at rest for heart
rate, systolic blood pressure and heart rate-blood pressure (HR x
BP) product. The bars represent mean ± standard error of the
mean (SEM) and results of statistical comparison (probability [p]
values) are presented on the right. NS = not significant.
Individual data (Fig. 5 to 7). When isosorbide dinitrate
was added to propranolol (Fig. 5), all patients had an in-
crease in exercise duration, although in some the improve-
ment was minimal. When nifedipine was added to pro-
pranolol (Fig. 6) exercise ability was improved in all but
one patient, and in general, the improvement was greater
than that obtained with isosorbide dinitrate.
Figure 7 shows the effects of combining isosorbide di-
nitrate with nifedipine in patients taking propranolol, but
using the exercise duration with propranolol plus nifedipine
rather than propranolol alone as a baseline. Because in gen-
eral the improvement was greater with nifedipine than with
isosorbide dinitrate, this method was used to determine if
there would be even greater improvement combining all
three drugs over the best combination of two. Interestingly,
there was a wide range of responses, with 2 patients ex-
periencing marked improvement, 10 patients showing only
either a slight increase or slight decrease in exercise duration
and 4 patients doing much worse with all three drugs than
with nifedipine and propranolol. If we also consider the 2
patients who became symptomatically hypotensive with all
three drugs, this means that in 11 of 18 patients exercise
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other than angina or had new symptoms in addition to an-
gina. The primary symptom noted was fatigue (six patients).
One patient became lightheaded, one completed the protocol
and one was stopped because of decreasing blood pressure
with exercise. Factors limiting exercise were similar with
the combination of all three agents in that eight patients
stopped for reasons other than angina (five with fatigue, one
with nausea, one with hip pain and one with arm pain).
Hemodynamic data at rest and during exercise (Fig.
1 to 3). Changes at rest (Fig. 1). The low heart rate at rest
and only moderate increase in rate during exercise confirm
that beta-adrenergic blockade in these patients was reason-
ably effective. The 4.6 beats/min increase in heart rate with
nifedipine was statistically significant but probably not clin-
ically important, and there was no significant change in heart
rate at rest with the addition of isosorbide dinitrate, or with
the combination of all three drugs. Systolic blood pressure
at rest decreased an average of 13.8 mm Hg with isosorbide
dinitrate, and an equivalent degree with nifedipine; but with
all three drugs there was a more significant decrease of 21.6
mm Hg. The rate-pressure product at rest decreased signif-
icantly only with the combination of all three drugs, and
this reduction was due to the decrease in blood pressure.
Changes with submaximal exercise (Fig. 2). All 16 pa-
tients were able to complete stage 11 of the exercise test on
every occasion. None of the drug combinations caused a
significant increase in heart rate at this submaximal level of
exercise. At this level, there was no longer any difference
between systolic blood pressure with nifedipine or isosor-
bide dinitrate compared with placebo, but the 15.6 mm Hg
decrease in blood pressure with the combination of iso-
sorbide dinitrate and nifedipine was significant (p < 0.005).
The rate-pressure product at 4 minutes of exercise was sim-
ilarly decreased with the combination of all three drugs (p
< 0.05), but was unchanged with isosorbide dinitrate or
nifedipine alone.
Changes with maximal exercise (Fig. 3). Similar to what
was noted at rest, heart rate at maximal exercise was altered
only by nifedipine. The systolic blood pressure was lower
with the combination of all three drugs (p < 0.01). The
rate-pressure product was statistically unchanged with any
combination of therapy when compared with propranolol
alone, but it did tend to be lower with triple drug therapy.
Exercise duration (Fig. 4 to 7). Total group (Fig. 4). For
the group as a whole, exercise was prolonged with both
isosorbide dinitrate (88.7 seconds longer than with pro-
pranolol alone) and with nifedipine (168.4 seconds longer),
but the increase with nifedipine was greater than that with
isosorbide dinitrate (p < 0.05). Exercise duration with iso-
sorbide dinitrate and nifedipine combined was also longer
than with propranolol alone, but there was no statistical
difference between this value and those with nifedipine or
isosorbide dinitrate given individually.
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Figure 2. Effect of various combinations of propranolol (P), iso-
sorbide dinitrate (I) and nifedipine (N) on heart rate, systolic blood
pressure and heart rate-blood pressure (HR x BP) product during
submaximal exercise. Format as in Figure I.
Figure 3. Effect of various combinations of propranolol (P), iso-
sorbide dinitrate (l) and nifedipine (N) on heart rate, systolic blood
pressure and heart rate-blood pressure (HR x BP) product during
maximal exercise. Format as in Figure I.
ability was worse with all three drugs than with propranolol
and nifedipine.
Discussion
Rationale for study design. With three different classes
of drugs available for treating angina pectoris, it is not
always clear which agent to choose when initiating therapy
for exercise-induced angina. A beta-adrenergic blocking agent
is often used as part of the medical regimen in such patients
because beta-blockers are of proven efficacy, reasonably
well tolerated and relatively convenient to take. They have
been available for many years so physicians are familiar
with their use, and perhaps they are also indicated because
recent studies (16-18) suggest they reduce mortality in sur-
vivors of acute myocardial infarction. However, additional
agents are often necessary when symptoms are not com-
pletely eliminated. For these reasons, we elected to test
combination vasodilator therapy in patients maintained on
a beta-adrenergic blocking agent. Because it is quite im-
practical to study all possible combinations of three different
agents used singly and then together, this approach allowed
us to examine several clinically pertinent therapeutic ques-
tions without an unduly long clinical trial.
Interpretation of results. The effects of using drugs in
combination cannot always be predicted based on the in-
dividual response to each administered separately. The drugs
used in this protocol have very different mechanisms of
action, and each has multiple direct and indirect effects on
the cardiovascular system. The potential benefit of combi-
nation therapy will, therefore, depend on the extent to which
favorable effects on myocardial oxygen supply and demand
are augmented, and adverse effects are canceled. Equally
important may be potential exacerbation or elimination of
side effects when multiple drugs are used together.
Isosorbide dinitrate plus propranolol. Our data confirm
the efficacy of adding isosorbide dinitrate to propranolol in
patients with angina pectoris. The therapeutic benefit of this
combination can be understood by considering individual
effects on myocardial oxygen supply and demand. Pro-
pranolol reduces myocardial oxygen demand by decreasing
ventricular systolic force, reducing heart rate and attenuating
the heart rate response to exercise (19-21). Isosorbide di-
nitrate acts primarily by decreasing cardiac preload and af-
terload. This produces a reflex increase in heart rate and
left ventricular contractility (22-24). By combining isosor-
bide dinitrate with propranolol, the oxygen-wasting tachy-
lACC Vol. 3, No.4
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Figure 4. Effect of various combinations of propranolol (P), iso-
sorbide dinitrate (I) and nifedipine (N) on exercise duration. Format
as in Figure I.
Figure 5. Change in exercise duration with propranolol and iso-
sorbide dinitrate combined (P + I) for each patient, using exercise
duration with propranolol alone (P) as baseline. The bars represent
the average change (± standard error of the mean) for the group
as a whole.
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Figure 6. Change in exercise duration with propranolol and ni-
fedipine combined (P + N) for each patient, using exercise du-
ration with propranolol alone (P) as baseline. The bars represent
the average change (± standard error of the mean) for the group.
cardia and increase in left ventricular contractility are di-
minished (25). Similarly, combining nitrates and propranolol
tends to balance their opposing effects on left ventricular
end-diastolic pressure (25,26). Nitrates also offset the in-
crease in peripheral vascular resistance produced by pro-
pranolol (27).
Nifedipine plus propranolol. Similar considerations are
valid for the combination of nifedipine and propranolol.
Nifedipine decreases afterload and enhances coronary blood
flow to ischemic myocardium (28,29). As with isosorbide
dinitrate, the beneficial effects are partially offset by the
reflex tachycardia induced by nifedipine. This baroreceptor
reflex is attenuated by concurrent administration of pro-
pranolol (3,30). In this study heart rate increased slightly
with nifedipine even though by usual clinical criteria the
patients were receiving adequate beta-adrenergic blockade
treatment.
Two drug therapy. Our results showed the combination
of propranolol and nifedipine to be more effective than the
combination of propranolol and isosorbide dinitrate in pro-
longing exercise tolerance. Caution must be used when com-
paring two drugs without complete dose-response curves for
each. This difference in drug response could simply be due
to differences in the effectiveness of the dosage chosen for
Figure 7. Change in exercise duration with propranolol, nifedi-
pine and isosorbide dinitrate combined (P + N + I) for each
patient, using exercise duration with propranolol and nifedipine
(P + N) as baseline. The bars represent the average change (±
standard error of the mean) for the group.
each drug. Even with this consideration, it is not readily
apparent why nifedipine was more effective than isosorbide
dinitrate. The decrease in blood pressure was equivalent
with each drug, while there was a slight increase in heart
rate with nifedipine not seen with isosorbide dinitrate in this
group of patients receiving propranolol. Thus, heart rate-
blood pressure product, an index of myocardial oxygen de-
mand, was not more favorably altered by nifedipine. Per-
haps factors affecting myocardial perfusion that were not
measurable in this study could account for the differences
noted. Patients with exercise-induced angina often represent
a mixed population in terms of relative amounts of fixed
coronary artery obstruction and of coronary artery spasm
contributing to their ischemia. Because propranolol alone
may increase the likelihood of coronary artery spasm (31),
the addition of nifedipine may benefit patients more than
the addition of isosorbide dinitrate; this depends on the
relative extent to which spasm contributes to the angina and
the extent to which nifedipine is more effective than iso-
sorbide dinitrate in reversing this vasoconstriction.
Three drug therapy. The combination of all three drugs
was effective in prolonging exercise tolerance when com-
pared with propranolol alone. However, compared with
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"optimal" two drug therapy with propranolol and nifedi-
pine, the condition of the majority of patients deteriorated
with the addition of a third agent (isosorbide dinitrate). The
mechanism accounting for this response remains unclear.
One possible mechanism may relate to the contrasting ben-
eficial and adverse effects of lowering blood pressure in
patients with angina. A decrease in blood pressure decreases
myocardial oxygen demand, but also lowers coronary per-
fusion pressure. The potent blood pressure-lowering re-
sponse to nifedipine combined with isosorbide dinitrate could
result in the adverse effects of lower perfusion pressure
predominating in some patients, whereas in others, the ben-
efit of decreased afterload is more important. The triple drug
combination produced a significant decrease in both blood
pressure and heart rate-blood pressure product at rest. How-
ever, we were unable to correlate any pre-exercise changes
in heart rate or blood pressure with exercise duration so that
we could predict which patients would have improved ex-
ercise tolerance with all three drugs.
Only 8 of 16 patients treated with all three drugs stopped
exercise because of chest pain. The triple drug combination
may alter the peripheral circulation so that leg fatigue or
dyspnea become the limiting factors in exercise tolerance,
before development of chest pain. It is possible that data
obtainable with more invasive hemodynamic studies could
help us better understand the variability in response to triple
drug therapy. Effects of the drugs on regional distribution
of peripheral blood flow, on blood flow within the heart to
ischemic and nonischemic areas and on coronary collateral
flow could all be important in determining the net results.
Limitations of study. This study was performed during
acute administration of the vasodilators, whereas the beta-
adrenergic blocker was given chronically. It is possible that
physiologic adjustments could occur with chronic vasodi-
lator therapy that might alter the results we observed in this
short-term study. It is also possible that the results could
vary depending on the particular beta-adrenergic blocker or
nitrate used. Because the blood pressure and heart rate re-
sponses to equivalent beta-adrenergic blocking doses of many
beta-adrenergic blockers are similar (32), we believe that
our results would be essentially unchanged had a different
beta-adrenergic blocker been chosen. It is also likely that
other nitrates would give similar results if equipotent doses
were used. Nevertheless, the cardiac and systemic effects
of other available calcium antagonists are disparate enough
that we would hesitate to extrapolate our results to predict
the response that might be obtained using verapamil or
diltiazem.
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